Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia : A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial
© 2023 LG Chem Ltd and The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology..
OBJECTIVE: To evaluate the safety and efficacy of the nonpurine xanthine oxidase inhibitor tigulixostat for lowering serum urate level in gout patients with hyperuricemia.
METHODS: We conducted a multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding trial. After screening, gout patients with hyperuricemia were randomly assigned, after appropriate washout, to receive daily oral administration of 50 mg, 100 mg, or 200 mg of tigulixostat, or placebo for 12 weeks. Colchicine gout flare prophylaxis was administered to all patients. The primary end point was the proportion of patients with a serum urate level <5.0 mg/dl at week 12.
RESULTS: A total of 143 patients were randomized to receive tigulixostat 50 mg (n = 34), 100 mg (n = 38), or 200 mg (n = 37), or placebo (n = 34). A significantly greater proportion of patients in the tigulixostat groups achieved the target serum urate level <5.0 mg/dl at week 12 (47.1% in the 50 mg group, 44.7% in the 100 mg group, and 62.2% in the 200 mg group) compared to the placebo group (2.9%) (P < 0.0001). The mean percentage change in serum urate level from baseline was also significantly greater in the tigulixostat groups (-38.8% to -61.8%) than in the placebo group at all time points (P < 0.0001). The rate of gout flares requiring rescue treatment ranged from 9.4% to 13.2% in the tigulixostat and placebo groups. The incidence of adverse events was 50.0% to 56.8% across all groups, and their severity was mild or moderate.
CONCLUSION: Tigulixostat significantly lowered serum urate compared to placebo at all doses studied with an acceptable safety profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Arthritis & rheumatology (Hoboken, N.J.) - 75(2023), 7 vom: 16. Juli, Seite 1275-1284 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Terkeltaub, Robert [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
101V0R1N2E |
|---|
| Anmerkungen: |
Date Completed 29.06.2023 Date Revised 02.07.2023 published: Print-Electronic CRiS: NCT03934099 Citation Status MEDLINE |
|---|
| doi: |
10.1002/art.42447 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351598634 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351598634 | ||
| 003 | DE-627 | ||
| 005 | 20231226051750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/art.42447 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351598634 | ||
| 035 | |a (NLM)36649008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Terkeltaub, Robert |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia |b A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2023 | ||
| 500 | |a Date Revised 02.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CRiS: NCT03934099 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 LG Chem Ltd and The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. | ||
| 520 | |a OBJECTIVE: To evaluate the safety and efficacy of the nonpurine xanthine oxidase inhibitor tigulixostat for lowering serum urate level in gout patients with hyperuricemia | ||
| 520 | |a METHODS: We conducted a multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding trial. After screening, gout patients with hyperuricemia were randomly assigned, after appropriate washout, to receive daily oral administration of 50 mg, 100 mg, or 200 mg of tigulixostat, or placebo for 12 weeks. Colchicine gout flare prophylaxis was administered to all patients. The primary end point was the proportion of patients with a serum urate level <5.0 mg/dl at week 12 | ||
| 520 | |a RESULTS: A total of 143 patients were randomized to receive tigulixostat 50 mg (n = 34), 100 mg (n = 38), or 200 mg (n = 37), or placebo (n = 34). A significantly greater proportion of patients in the tigulixostat groups achieved the target serum urate level <5.0 mg/dl at week 12 (47.1% in the 50 mg group, 44.7% in the 100 mg group, and 62.2% in the 200 mg group) compared to the placebo group (2.9%) (P < 0.0001). The mean percentage change in serum urate level from baseline was also significantly greater in the tigulixostat groups (-38.8% to -61.8%) than in the placebo group at all time points (P < 0.0001). The rate of gout flares requiring rescue treatment ranged from 9.4% to 13.2% in the tigulixostat and placebo groups. The incidence of adverse events was 50.0% to 56.8% across all groups, and their severity was mild or moderate | ||
| 520 | |a CONCLUSION: Tigulixostat significantly lowered serum urate compared to placebo at all doses studied with an acceptable safety profile | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 650 | 7 | |a Gout Suppressants |2 NLM | |
| 650 | 7 | |a Febuxostat |2 NLM | |
| 650 | 7 | |a 101V0R1N2E |2 NLM | |
| 700 | 1 | |a Lee, Jisoo |e verfasserin |4 aut | |
| 700 | 1 | |a Min, Jiyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Seonghye |e verfasserin |4 aut | |
| 700 | 1 | |a Saag, Kenneth G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology (Hoboken, N.J.) |d 2014 |g 75(2023), 7 vom: 16. Juli, Seite 1275-1284 |w (DE-627)NLM234543671 |x 2326-5205 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g number:7 |g day:16 |g month:07 |g pages:1275-1284 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/art.42447 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |e 7 |b 16 |c 07 |h 1275-1284 | ||